A phase 3, double-blind, placebo-controlled study of maintenance pemetrexed plus best supportive care versus best supportive care immediately following induction treatment for advanced non-small cell lung cancer.
Phase of Trial: Phase III
Latest Information Update: 29 Jan 2015
At a glance
- Drugs Pemetrexed (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly
- 13 Feb 2012 Quality-of-life results published in the Lancet Oncology.
- 27 Sep 2011 Actual end date changed from Mar 2010 to Dec 2011 as reported by ClinicalTrials.gov.
- 20 Sep 2009 Primary endpoint 'Progression free survival duration' has been met according to results published in the Lancet.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History